MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

131.21 +4.12 (+3.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
3 Cash-Producing Stocks We Think Twice About
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
News headline image
AMN Healthcare Services, NeoGenomics, Acadia Healthcare, BrightSpring Health Services, and Repligen Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Stocks
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 29, 2025 ↗
 
Via Benzinga
News headline image
RGEN Q2 Deep Dive: Chromatography and Filtration Drive Growth, Guidance Lifted Amid New Modalities Uncertainty
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) announced better-than-expected revenue in Q2 CY2025, with sales up 14.8% year on year to $182.4 million. The company’s full-year... 
Via StockStory
News headline image
1 Safe-and-Steady Stock on Our Buy List and 2 We Turn Down
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Repligen Stock Outlook: Risk Skewed To The Downside Through 2026 ↗
Repligen stock has been in a prolonged downtrend, and Adhishthana principles suggest more weakness ahead. Here's what investors should track... 
Via Benzinga
News headline image
Why Repligen (RGEN) Stock Is Up Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.8% in the morning session after the company reported strong second-quarter 2025 financial results and raised its... 
Via StockStory
Topics Artificial Intelligence Lawsuit
News headline image
Repligen Corp (NASDAQ:RGEN) Q2 2025 Earnings: Revenue Beat Offsets EPS Miss as Stock Rises in Pre-Market ↗
Repligen Corp's Q2 2025 earnings show revenue beat estimates at $182.4M, but EPS missed at $0.37. Stock rose 2.65% pre-market amid strong order growth. 
Via Chartmill
News headline image
Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 14.8% year on year to $182.4 million. The... 
Via StockStory
News headline image
Repligen (RGEN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting earnings this Tuesday before the bell. Here’s what to look for. 
Via StockStory
News headline image
Forecasting The Future: 6 Analyst Projections For Repligen ↗
 
Via Benzinga
News headline image
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit
News headline image
1 Healthcare Stock to Target This Week and 2 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
News headline image
What Analysts Are Saying About Repligen Stock ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
1 Unprofitable Stock for Long-Term Investors and 2 to Ignore
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
News headline image
Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks
Let’s dig into the relative performance of Repligen (NASDAQ:RGEN) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season. 
Via StockStory
News headline image
Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Repligen (NASDAQ:RGEN) and the best and... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks in Hot Water
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
News headline image
1 High-Flying Stock with Exciting Potential and 2 to Keep Off Your Radar
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,... 
Via StockStory
News headline image
Deep Dive Into Repligen Stock: Analyst Perspectives (8 Ratings) ↗
 
Via Benzinga
News headline image
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 10.4% year on year to $169.2 million. The company’s... 
Via StockStory
Topics World Trade
News headline image
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.4% year on year to $169.2 million. The... 
Via StockStory
Topics World Trade
News headline image
Repligen (RGEN) Q1 Earnings: What To Expect
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Topics World Trade
News headline image
3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
News headline image
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?
Repligen trades at $120.32 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 10.5% while the S&P 500 is down 7.7%. This might have investors... 
Via StockStory
Topics Stocks
News headline image
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story